Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells

Death Receptors: Signaling and Modulation

1998 • 5,873 citations

Cancer statistics, 1999

1999 • 3,154 citations

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

1994 • 2,575 citations

IAP family proteins---suppressors of apoptosis

1999 • 2,570 citations

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

1999 • 2,494 citations

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

1997 • 1,694 citations

Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in Culture

1991 • 1,459 citations

Apoptosis control by death and decoy receptors

1999 • 1,296 citations

Mechanisms of Apoptosis

2000 • 1,249 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

Apoptosis signaling by death receptors

1998 • 976 citations

Mechanism-Based Target Identification and Drug Discovery in Cancer Research

2000 • 607 citations

Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

1999 • 557 citations

Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design

1994 • 521 citations

Loss of DNA mismatch repair in acquired resistance to cisplatin.

1996 • 505 citations

Overexpression and mutation of p53 in epithelial ovarian cancer.

1991 • 464 citations

Clinical and pharmacological studies with cis-diamminedichloroplatinum (II).

1973 • 430 citations

Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

1999 • 394 citations

Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

2000 • 391 citations

Molecular determinants of response to TRAIL in killing of normal and cancer cells.

2000 • 379 citations

p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.

1998 • 363 citations

p53 in signaling checkpoint arrest or apoptosis

1996 • 336 citations

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

1993 • 311 citations

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

1992 • 305 citations

Mechanisms of p53-mediated apoptosis

1999 • 303 citations

Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.

1988 • 281 citations

Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL

2000 • 259 citations

The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.

1996 • 232 citations

The caspase family of cysteine proteases

1997 • 227 citations

Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of Neurotoxicity

1999 • 214 citations

Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.

1992 • 213 citations

Chemotherapeutic Agents Augment TRAIL-Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines

2000 • 205 citations

Cell death: TRAIL and its receptors

1997 • 196 citations

Death and decoy receptors and p53-mediated apoptosis

2000 • 192 citations

Advanced epithelial ovarian cancer: 1993 consensus statements

1993 • 191 citations

Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L–induced apoptosis of human acute leukemia cells

2000 • 184 citations

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.

1995 • 183 citations

Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies

1997 • 124 citations

Untitled

1999 • 123 citations

Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells

2000 • 121 citations

Mechanisms and modulation of resistance to chemotherapy in ovarian cancer

1993 • 113 citations

Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest

1999 • 111 citations

Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines

2000 • 107 citations

Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells

1999 • 105 citations

Mechanisms of drug resistance in ovarian cancer

2010 • 98 citations

p21WAF1/CIP1 Inhibits Initiator Caspase Cleavage by TRAIL Death Receptor DR4

2000 • 97 citations

TRAIL Death Pathway Expression and Induction in Thyroid Follicular Cells

1999 • 91 citations

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

1999 • 78 citations

Chemotherapy resistance in ovarian cancer: New molecular perspectives

1998 • 70 citations

Update of the NCCN ovarian cancer practice guidelines.

1997 • 66 citations

Regulation of TRAIL-Induced Apoptosis by Transcription Factors

2000 • 63 citations

Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.

1999 • 60 citations

Control of apoptosis signaling by Apo2 ligand.

1999 • 57 citations

Adenovirus-Mediated p53 Growth Inhibition of Ovarian Cancer Cells Is Independent of Endogenous p53 Status

1999 • 54 citations

Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).

2000 • 52 citations

Protein binding of anthraquinone glycosides, with special reference to adriamycin

1982 • 52 citations

Biological therapy of ovarian cancer: current directions.

1998 • 50 citations

Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer

1997 • 48 citations

The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms

2000 • 44 citations

Role of p53 in drug resistance in ovarian cancer

1997 • 41 citations

Drug resistance in ovarian cancer — the role of p53

1998 • 40 citations

Drug resistance in ovarian cancer: from the laboratory to the clinic

1998 • 35 citations

Multiple Drug Resistance Parameter Expression in Ovarian Cancer

1998 • 33 citations

Intraperitoneal therapy in the management of ovarian carcinoma.

1989 • 20 citations

Clinical study of multi-drug resistance gene (MDR1) expression in primary ovarian cancer

1998 • 4 citations